Trans-arterial embolization for hepatocellular carcinoma: doxorubicin is not necessary

Karen T. Brown; Richard Kinh Do; Mithat Gonen; Anne M. Covey; George I. Getrajdman; Constintinos T. Sofocleous; William R. Jarnagin; Michael I. D’Angelica; Peter J. Allen; Joseph P. Erinjeri; Lynn A. Brody; Stephen B. Solomon; Lawrence H. Schwartz; Ronald P. DeMatteo; Ghassan K. Abou-Alfa

doi:10.21037/tcr.2016.11.60

Correspondence

Trans-arterial embolization for hepatocellular carcinoma: doxorubicin is not necessary

Karen T. Brown, Richard Kinh Do, Mithat Gonen, Anne M. Covey, George I. Getrajdman, Constintinos T. Sofocleous, William R. Jarnagin, Michael I. D’Angelica, Peter J. Allen, Joseph P. Erinjeri, Lynn A. Brody, Stephen B. Solomon, Lawrence H. Schwartz, Ronald P. DeMatteo, Ghassan K. Abou-Alfa

Abstract

Drs. Cucchetti, Cappelli and Golfieri clearly have an in depth knowledge of the principles and practice of trans-arterial chemoembolization and bland hepatic arterial embolization (HAE) for HCC (1).

Correspondence

Trans-arterial embolization for hepatocellular carcinoma: doxorubicin is not necessary

Abstract

Article Options

Download Citation

Share